Allos new drug application to be reviewed by FDA panel

May 2004
PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p7
Market Research Report
Reports on Allos Therapeutics' disclosure that the oncologic drugs advisory committee of the U.S. Food and Drug Administration plans to review the company's investigational radiation sensitizer, RSR13, on May 3, 2004. Mechanism of action of the drug; Agency's acceptance of the company's new drug application seeking approval to market RSR13 as brain radiation therapy in February 2004.


Related Articles

  • Allos applies for approval of cancer therapy.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p8 

    Reports that Allos Therapeutics' is submitting a New Drug Application to the U.S. Food and Drug Administration to market RSR13 as a treatment for brain metastases from breast cancer. Fast-track designation of RSR13 (efaproxiral) from the FDA; Results of the drug in patients with metastatic...

  • Allos' Folotyn Strategy in Solid Tumors May Avoid Large Trials. Morrison, Trista // BioWorld Insight;6/14/2010, Vol. 18 Issue 24, p2 

    The article reports on the expectation of Allos Therapeutics Inc. to earn U.S. Food and Drug Administration's (FDA's) approval of its cancer drug Folotyn (pralatrexate) without conducting Phase III trials. Allos chose an indication with severe unmet medical need such as the peripheral T-cell...

  • Cancer.  // PharmaWatch: Monthly Review;May2009, Vol. 8 Issue 5, p4 

    The article offers news briefs related to pharmaceutical industry in the U.S. A new drug application has been submitted by Allos Therapeutics Inc. to the Food and Drug Administration (FDA) for the use of pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell...

  • Allos' PDX Yields Positive Data in PTCL Trial.  // Bioworld Week;5/19/2008, Vol. 16 Issue 20, p4 

    The article discusses the results of the Phase II study of PDX (pralatrexate) from Allos Therapeutics Inc. in peripheral T-cell lymphoma. Out of 65 patients, 19 of them experienced either a complete or partial response when treated with PDX. The drug will need to show at least a 20 percent...

  • Go Ask Allos: Pralatrexate Next Rituxan Up Lymphoma Ladder? Osborne, Randy // BioWorld Insight;8/3/2009, Vol. 17 Issue 31, p3 

    The article discusses the issue concerning the approval of the use of pralatrexate in peripheral T-cell lymphoma (PTCL) developed by Westminster, Colorado-based Allos Therapeutics Inc. It views on the concern of several investors whether the drug will gain an approval from the U.S. Food and Drug...

  • FDA approves pralatrexate for treatment of rare lymphoma. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;11/1/2009, Vol. 66 Issue 21, p1890 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Pralatrexate (Folotyn) from Allos Therapeutics Inc. for peripheral T-cell lymphoma treatment. It mentions that Pralatrexate is the first drug approved by the FDA for the treatment of the rare disease which occurs...

  • No Cure for Cancer? Wall Street Waits - and Hesitates. O'Connell, Brian // BioPharm International;Sep2005, Vol. 18 Issue 9, p18 

    Reports on the issues surrounding the development of drugs to treat cancer by pharmaceutical companies in the U.S. Search of Pfizer Inc. for a regulatory approval for its new drug Sutent that targets stomach and kidney cancers; Provision of conditional approval to the new cancer drug by the Food...

  • FDA clears first drug for rare asbestos-related cancer. Vecchione, Anthony // Drug Topics;3/8/2004, Vol. 148 Issue 5, p24 

    Reports on the approval of the U.S. Food and Drug Administration on the marketing of Eli Lilly & Co.'s Alimta for the treatment of patients with malignant pleural mesothelioma who are not candidates for resection or curative surgery. Details on how to use the drug; Availability of the drug;...

  • FDA Update.  // Pharmaceutical Representative;Sep2011, Vol. 41 Issue 9, p11 

    The article offers updates related to the U.S. Food and Drug Administration (FDA). The treatment for inoperable medullary thyroid cancer of AstraZeneca PLC has received its approval from FDA. The agency has approved the first specific treatment for scorpion stings in the country. Pharmaceutical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics